Nucleai is creating AI-driven spatial biomarkers, and uses AI to create a map of cells in biopsy tissue samples that can provide all-important information for a personalised treatment approach.
“We couldn’t find these relationships using traditional methods, so we started working with Nucleai who had the right tools.”
“We have developed an AI-driven spatial biology solution that maps cells in biopsies and correlates these maps with other layers of information,” says Avi Veidman, Nucleai’s CEO and cofounder. “In an era where new oncological drugs target specific proteins, Nucleai’s solution identifies which patients will respond to these drugs and which are suitable for clinical trials of newly developed treatments.”
Digitised tissue samples can unlock information about more than just one cell.
“Our platform maps the neighbourhood of cells, providing more context and insight into the interplay of cells. This allows pharmaceutical companies to increase the probability of success in clinical trials and enables oncologists to treat patients with the most effective drugs,” says Veidman.
